Efficacy and pharmacokinetics of subcutaneous exendin (9â39) in patients with post-bariatric hypoglycemia
Diabetes, Obesity and Metabolism Aug 10, 2017
Craig CM, et al. – Aim of this current study was to evaluate the adequacy, pharmacokinetics and tolerability of subcutaneous (SC) Ex–9 in patients with post–bariatric hypoglycemia (PBH). It was showed that SC Ex–9 appears to represent a safe, effective, and targeted therapeutic approach for treatment of PBH. Future study involving multiple doses with chronic dosing is warranted.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
